focuses on generics and APIs with strong presence in India and regulated markets. It has built a pipeline of US generics and specialty products to drive future growth. Backward integration and R&D investments aid cost competitiveness. Risks arise from US price erosion, regulatory inspections, and product concentration in key molecules.

#WatchOutFor#FundamentalViews#TechnicalViews#Miscellaneous#EquityResearch

520 likes·38 comments